Research & Development

Advancing cellular therapy

Vericel Corporation is a leader in the development of autologous (patient’s own) cell therapies for the treatment of serious medical conditions. Cell therapy is the infusion, injection or transplantation of whole cells back into a patient for treatment of the condition. The goal of cell therapy is to repair or restore damaged tissues or organs.

How does cell therapy work?

In autologous cell therapy, the patient is the source (donor) of their own therapy. Their own tissue is collected by a qualified and trained surgeon, and then processed and expanded by Vericel into a specific cell type or multicellular therapy. The cells are then returned to the surgeon for implantation. With the patient acting as their own donor, the risk of rejection and the use immunosuppressive therapy is minimized.

Vericel uses a proprietary cell-processing manufacturing technology to expand naturally occurring populations of cells derived from the patient’s tissue. In the first step of the process, a small tissue sample is taken from the patient. The tissue sample taken is dependent on the type of therapy needed, and contains a range of cells known to play important roles in the natural healing mechanisms of the human body. Through research and clinical development it has been shown that Vericel’s proprietary cell manufacturing processes yield a mixture of cell types with diverse properties that promote long-term tissue repair in patients with serious medical conditions. Contact us with questions about our research and development or manufacturing processes.

Vericel’s therapy pipeline includes innovative cell based therapies in developmentand on the market for patients with serious diseases and conditions.

Autologous Cell Therapy

Vericel’s current portfolio is specific to autologous (patient’s own) “For Me, By Me” cell therapies. Autologous means that the source of our therapies comes directly from the patient’s own cells in the form of small amounts of tissue like bone marrow, skin, or knee cartilage.

Once received at one of our manufacturing sites, the tissue is processed and expanded into a specific cell therapy or a multicellular therapy and returned to the patient to be implanted. In the end, our patients own cells are the source of their treatment. Because a patient’s own cells are used, it minimizes both the risk of rejection and the use of immunosuppressive therapy pre- or post-therapy.

Product Development Programs

From Tissue to Treatment. The unique manufacturing arc begins with the patient’s own tissue and ultimately delivers a life-enhancing cell therapy to that same patient. The Process: From collection to isolation…to expansion and finally to implantation.

Ixmyelocel‑T is an autologous (patient’s own), expanded multicellular therapy, manufactured using Vercel’s proprietary, highly automated, fully closed cell-processing system.

Clinical Research

Currently, Vericel has no active clinical trials being recruited.

What is a clinical trial?

To learn more about clinical trials, visit ClinicalTrial.gov, a registry of federally and privately supported clinical trials conducted in the United States and around the world, or contact us with questions about our clinical development process.

Targets in Clinical Development: Cardiomyopathy
Dilated cardiomyopathy (DCM), a progressive disease of heart muscle, is a leading form of heart failure (HF) and the most frequent cause of heart transplantation. The word dilated refers to the enlarged state of the heart in DCM, and the word cardiomyopathy means disease of the heart muscle. Cardiomyopathy damages the heart muscle and reduces the ability to pump blood throughout the body. Below is information about the status of Vericel’s DCM clinical trials.

Active Trials in Clinical Development

IXCELL-DCM (55-1202-1)

ixcell_dcm_logo

 

Status: Not Recruiting
Study design: Phase 2b, double blind, placebo controlled, prospective, randomized, multicenter
Patients: Patients must have a diagnosis of ischemic dilated cardiomyopathy based on WHO criteria, symptomatic heart failure in NYHA class III or IV, left ventricular ejection fraction of less than or equal to 30%, and no other cardiac intervention options likely to improve clinical status.
Purpose: To assess the efficacy and safety of ixmyelocel-T delivered by catheter and transendocardial injection in patients with DCM.
Publications Based On Study: None
You may also view more complete information about this study (55-1202-1) on ClinicalTrials.gov, a registry of clinical trials conducted in the United States and around the world.

Read the full study here

 

Scientific Publications

Key publications, presentations and abstracts of Vericel Corporation are listed in chronological order below and available for download in PDF.